SICAL calcitriol 0.25 microgram capsule blister pack Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

sical calcitriol 0.25 microgram capsule blister pack

alphapharm pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow - sical is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. sical a is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. sical is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

CALCITRIOL capsule, liquid filled Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

calcitriol capsule, liquid filled

bryant ranch prepack - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyro

CALCITRIOL capsule, liquid filled Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

calcitriol capsule, liquid filled

bryant ranch prepack - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. c

Calcipotriol HEXAL 0.05 mg/g Malta - Tiếng Anh - Medicines Authority

calcipotriol hexal 0.05 mg/g

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - calcipotriol - ointment - calcipotriol 50 µg/g - antipsoriatics

CALCITRIOL solution Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

calcitriol solution

patrin pharma, inc - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. calcitriol should not be given to patients with hypercalcemia or evidence of vitamin d toxicity. use of calcitriol in patients with known hypersensitivity to calcitriol (or drugs of the same class) or any of the inactive ingredients is contraindicated.

Calcitriol 0.5mcg Capsules Malta - Tiếng Anh - Medicines Authority

calcitriol 0.5mcg capsules

p & d pharmaceuticals limited - calcitriol - capsule - calcitriol 0.5 µg - vitamins

Calcitriol 0.5 microgram Capsules Malta - Tiếng Anh - Medicines Authority

calcitriol 0.5 microgram capsules

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - calcitriol - soft capsule - calcitriol 0.5 µg - vitamins

DAIVOBET 50/500 calcipotriol 50 microgram/g and betamethasone (as dipropionate) 500 microgram/g ointment tube Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

daivobet 50/500 calcipotriol 50 microgram/g and betamethasone (as dipropionate) 500 microgram/g ointment tube

leo pharma pty ltd - calcipotriol, quantity: 50 microgram/g; betamethasone dipropionate, quantity: 643 microgram/g (equivalent: betamethasone, qty 500 microgram/g) - ointment - excipient ingredients: liquid paraffin; polyoxypropylene-11 stearyl ether; dl-alpha-tocopherol; white soft paraffin; butylated hydroxytoluene - daivobet ointment is indicated for the once daily topical treatment of plaque-type psoriasis vulgaris amenable to topical therapy.

DAIVOBET 50/500 calcipotriol 50 microgram/g and betamethasone (as dipropionate) 500 microgram/g gel bottle Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

daivobet 50/500 calcipotriol 50 microgram/g and betamethasone (as dipropionate) 500 microgram/g gel bottle

leo pharma pty ltd - calcipotriol, quantity: 50 microgram/g; betamethasone dipropionate (equivalent: betamethasone, qty 500 microgram/g) - gel - excipient ingredients: nitrogen; hydrogenated castor oil; polyoxypropylene-11 stearyl ether; butylated hydroxytoluene; liquid paraffin; dl-alpha-tocopherol - topical treatment of scalp psoriasis. topical treatment of mild to moderate plaque psoriasis on the body in adults.